Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …
P2Y12 platelet inhibition in clinical practice
P Damman, P Woudstra, WJ Kuijt, RJ de Winter… - Journal of thrombosis …, 2012 - Springer
Platelet adhesion, activation and aggregation play a pivotal role in atherothrombosis.
Intracoronary atherothrombosis is the most common cause of the development of acute …
Intracoronary atherothrombosis is the most common cause of the development of acute …
[HTML][HTML] Bedside monitoring to adjust antiplatelet therapy for coronary stenting
Background Patients' responses to oral antiplatelet therapy are subject to variation. Bedside
monitoring offers the opportunity to improve outcomes after coronary stenting by …
monitoring offers the opportunity to improve outcomes after coronary stenting by …
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with …
D Trenk, GW Stone, M Gawaz, A Kastrati… - Journal of the American …, 2012 - jacc.org
Objectives: This study sought to investigate the efficacy, safety, and antiplatelet effect of
prasugrel as compared with clopidogrel in patients with high on-treatment platelet reactivity …
prasugrel as compared with clopidogrel in patients with high on-treatment platelet reactivity …
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
Background Prospective assessment of pharmacogenetic strategies has been limited by an
inability to undertake bedside genetic testing. The CYP2C19* 2 allele is a common genetic …
inability to undertake bedside genetic testing. The CYP2C19* 2 allele is a common genetic …
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project
JM Pulley, JC Denny, JF Peterson… - Clinical …, 2012 - Wiley Online Library
The promise of “personalized medicine” guided by an understanding of each individual's
genome has been fostered by increasingly powerful and economical methods to acquire …
genome has been fostered by increasingly powerful and economical methods to acquire …
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function …
Context The relationship of platelet function testing measurements with outcomes in patients
with acute coronary syndromes (ACS) initially managed medically without revascularization …
with acute coronary syndromes (ACS) initially managed medically without revascularization …
Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and …
MJ Price, SS Murray, DJ Angiolillo, E Lillie… - Journal of the American …, 2012 - jacc.org
Objectives: This study sought to evaluate the influence of single nucleotide polymorphisms
(SNPs) on the pharmacodynamic effect of high-or standard-dose clopidogrel after …
(SNPs) on the pharmacodynamic effect of high-or standard-dose clopidogrel after …
Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms
JP Cruz, M Chow, C O'Kelly, B Marotta… - American journal …, 2012 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: The PED is a flow-diverting stent designed for the
treatment of cerebral aneurysms. We report 4 cases of delayed ipsilateral IPH following the …
treatment of cerebral aneurysms. We report 4 cases of delayed ipsilateral IPH following the …
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
Aims The aim of this study was to compare on-thienopyridine platelet reactivity of elderly
patients (≥ 75 years) vs. younger patients (< 75 years). Elderly patients represent a growing …
patients (≥ 75 years) vs. younger patients (< 75 years). Elderly patients represent a growing …